Review: cellular senescence in metabolic dysfunction-associated steatotic liver disease
This abstract describes a review arguing that senescent liver cells of several types contribute to MASLD progression, and that senescence-targeting therapies remain preclinical with unresolved specificity and safety issues. [1]
Automatic summary · not editorially reviewed
The key findings
The abstract states that senescence occurs in hepatocytes and also in hepatic stellate cells, Kupffer cells and liver sinusoidal endothelial cells in MASLD. [1]
These senescent cells are described as promoting MASLD progression through cell type-specific mechanisms and intercellular communication. [1]
Senolytics, senomorphics and immune-mediated clearance showed potential in preclinical studies, while clinical translation faces heterogeneity, specificity and safety concerns. [1]
The source at a glance
- Study type / format
- Review (abstract only)
- Population / context
- People with metabolic dysfunction-associated steatotic liver disease, as discussed in a review
- Summary based on
- Study abstract
- Original publication
- July 9, 2026
Senescence across liver cell types in MASLD
The review concerns MASLD, described as the most prevalent chronic liver disease worldwide, marked by hepatic steatosis, inflammation and progressive fibrosis. Cellular senescence is defined here as an irreversible cell-cycle arrest with metabolic reprogramming and changes in secretory phenotype. According to the abstract, current evidence indicates senescence occurs not only in hepatocytes but also in non-parenchymal cells: hepatic stellate cells, Kupffer cells and liver sinusoidal endothelial cells. These senescent cells are said to promote progression through cell type-specific mechanisms and intercellular communication.
Supporting source [1]
Senolytics and clearance approaches only preclinical
The abstract states that targeting cellular senescence has emerged as a promising therapeutic strategy for MASLD. Senolytics, senomorphics and immune-mediated clearance approaches have shown potential in preclinical studies. However, clinical translation is described as challenged by cellular heterogeneity, target specificity and safety concerns. The review is said to evaluate these strategies and provide a conceptual framework for future clinical translation; no human trial results are reported in the abstract.
Supporting source [1]
Abstract-only scope of this review summary
The supplied text is an abstract of a review, not a primary study, so no sample size, follow-up or outcome data are given. The mechanistic and therapeutic statements are presented as the review's synthesis of current evidence. Because only the abstract was available, the full text was not reviewed, and details of how studies were selected or evaluated cannot be checked here.
Supporting source [1]
How to interpret this
Abstract only; the full text was not reviewed. No study design, sample, follow-up or outcome data are reported, and the therapeutic statements rest on preclinical evidence.
Based on the study abstract; the full paper, tables and supplementary data were not reviewed.
Source & supporting passages
Wen R, Wang H, Xie J, Lin X, Wang S. · europepmc.org · July 9, 2026